ImmuCell Corporation (NASDAQ: ICCC) reported preliminary first-quarter sales of $10.4 million for the period ended March 31, 2026, representing a 28.4% increase from $8.1 million in the same period last year, according to a company statement.

The animal health biologics company's domestic sales reached $9.7 million, up 35.7% from the prior year, while international sales declined 30.2% to $0.6 million. Sales of the company's Tri-Shield product totaled $7.9 million, a 38.5% increase, while Dual Force and other products generated $2.5 million in sales, up 4.4%.

"We had outstanding first quarter sales performance driven by our Tri-Shield product," said Olivier te Boekhorst, President and CEO. "This gives us confidence that our strategy of focusing on First Defense is working."

Timothy C. Fiori, Chief Financial Officer, attributed the results to seasonal demand from the cow-calf segment during the company's peak selling season from November through February. He noted that previous backorder situations continue to create challenges with predicting growth rates in 2026.

The company has hired a leader for international commercial efforts and two domestic field sales managers to support growth, according to Senior Vice President of Sales and Marketing Bobbi Jo Brockmann.

ImmuCell plans to host a conference call on May 15, 2026, at 9:00 AM ET to discuss the unaudited financial results. The Portland, Maine-based company develops and manufactures products to improve calf health and productivity.